



EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

17 June 2026
EMA/135300/2026
Regulatory Science and Innovation Task Force

Agenda — Medicine Shortages SPOC Working Party

16 June 2026, from 10:00 to 18:00 (CET), hybrid meeting – F2F + TEAMS

17 June 2026, from 09:00 to 16:00 (CET), hybrid meeting – F2F + TEAMS

Health and safety information

In accordance with Agency policy, delegates are to be shown a slide show with health and safety and emergency information and procedures. This is to be displayed at the start of this meeting using the Crestron system as delegates are entering the meeting room. In addition, the chairperson or meeting secretariat is to draw the delegates' attention to the slideshow and indicate where the nearest fire exit(s) to the meeting room are. Should there be an evacuation during the meeting, staff will guide delegates out of the building via the nearest fire exit and assist anyone with a mobility impairment.

Chair: Monica Dias (EMA), Vice-Chair: Vasileios Loutas (PhS, Ministry of Health, Cyprus)

Tuesday, 16 June 2026 (10:00-18:00)

Item	Topic
1.	Welcome, declarations of interest, adoption of draft agenda
2.	Adoption of draft minutes of the SPOC WP meeting held on 12 May 2026

Official address Domenico Scarlattilaan 6 • 1083 HS Amsterdam • The Netherlands
Address for visits and deliveries Refer to www.ema.europa.eu/how-to-find-us
Send us a question Go to www.ema.europa.eu/contact **Telephone** +31 (0)88 781 6000

An agency of the European Union



Tuesday, 16 June 2026 (10:00-18:00)

Item	Topic
3.	Updates from Member States
	a) SPOC WP lightning round – most critical issues at national level
	b) Status update on any new strategic measures implemented at national level (e.g., critical medicines lists, stockpiling requirements)
4.	Potential impact of the international situation on the supply of medicinal products for human and veterinary use to the European market: <ul style="list-style-type: none">• Update on the geopolitical situation• Hantavirus and Ebola – Situation update
5.	Oral status update on the availability of human and veterinary medicines in MSs (only for new emerging information)
6.	Critical shortages escalated to the SPOC Working Party:
6.1	Ongoing shortages
	a) Ifosfamide containing medicinal products and cyclophosphamide containing medicinal products
	b) Availability of anti-tuberculosis medicines
	c) Medicinal products manufactured by Pharmathen International site
	d) Fibclot NAP (human fibrinogen), MAH: Laboratoire français du Fractionnement et des Biotechnologies S.A.
	e) Azactam NAP (aztreonam), MAH: Delbert Pharma
	f) Medicinal products from MAH Cheplapharm
7.	EC DG SANTE update
8.	Implementation of the New Pharmaceutical Legislation: Provisions related to shortages and security of supply
9.	Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG)-led activities: <ul style="list-style-type: none">a) Feedback from the MSSG meeting on 20 May 2026 and ad-hoc MSSG meeting on 12 June 2026b) Feedback from the MSSG WG on the Vulnerability Assessment including Shortage Prevention Plansc) Union list of critical medicines and Union long list - update

Wednesday, 17 June 2026 (09:00-16:00)

Item	Topic
10.	National competent authorities on pricing and reimbursement and public healthcare payers (NCAPR) <ul style="list-style-type: none">• NCAPR and its objectives• Using pricing policy to improve the availability of medicines
11.	Impact of marketing authorisation withdrawals and permanent marketing cessations of medicinal products in the EU/EEA
12.	Drug Shortage Global Regulatory Working Group: feedback from Q2 meeting
13.	Short shelf-life of medicinal products and its impact on the availability
14.	Shortage management systems:
	a) Belgium – Approach in ensuring interoperability with EMA systems
	b) European Shortages Monitoring Platform (ESMP) update
	c) Bulgaria - EMVS data: market monitoring and use by MS
15.	SPOC WP subgroup on shortage definition – Proposal for update of root cause classification
16.	Status update on other critical shortages escalated to the SPOC WP (only comments relating to previously circulated written updates)
	a) Medicinal products affected by fire incident at Viatris manufacturing site
	b) Creon NAP (pancrelipase), MAH: Viatris
17.	AOB
18.	Wrap-up and next steps
19.	Closing remarks

Next meeting: 15 July 2026 (TEAMS)
